WHO study says remdesivir did not cut hospital stay or mortality in Covid-19 patients. Same with hydroxychloroquine, anti-HIV drug combination lopinavir/ritonavir and interferon

‘Gilead Sciences Inc's GILD.O remdesivir had little or no effect on COVID-19 patients' length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) has found. The antiviral medication, among the first to be used as a treatment for COVID-19, was one of the drugs recently used to treat U.S. President Donald Trump’s coronavirus infection.

‘The results are from WHO’s “Solidarity” trial, which evaluated the effects of four potential drug regimens, including remdesivir, hydroxychloroquine, anti-HIV drug combination lopinavir/ritonavir and interferon, in 11,266 adult patients across more than 30 countries. The study found the regimens appeared to have little or no effect on 28-day mortality or the length of the in-hospital course among patients hospitalized with COVID-19, the WHO said on Thursday.’

Read here (Reuters, Oct 16, 2020)

Protein treatment trial ‘a breakthrough’

‘The preliminary results of a clinical trial suggest a new treatment for Covid-19 dramatically reduces the number of patients needing intensive care, according to the UK company that developed it. The treatment from Southampton-based biotech Synairgen uses a protein called interferon beta which the body produces when it gets a viral infection... The initial findings suggest the treatment cut the odds of a Covid-19 patient in hospital developing severe disease - such as requiring ventilation - by 79%.’

Read here (BBC, July 20, 2020